A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/20/2019 |
| Start Date: | February 14, 2019 |
| End Date: | February 2021 |
| Contact: | Paul Chapman, MD |
| Email: | chapmanp@mskcc.org |
| Phone: | 646-888-4162 |
Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?
The purpose of this study is to find out what patients consider when deciding whether or not
to receive adjuvant treatment, and how patients feel about their decision after one year.
to receive adjuvant treatment, and how patients feel about their decision after one year.
Inclusion Criteria:
- Cutaneous melanoma rendered free of disease by surgical resection.
- Histologic proof of melanoma reviewed and confirmed by MSK.
- Patients are being offered adjuvant nivolumab therapy
- Patient has not yet formally discussed their treatment options with their Medical
Oncologist.
- Age 18 or older.
- Ability to speak and read English because we do not have the resources to translate
materials into other languages.
Exclusion Criteria:
- Patient not currently free of disease.
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Paul Chapman, MD
Phone: 646-888-4162
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
